Why Is Hemoglobin Not Increasing After Transfusion?

A single unit of red blood cells is generally expected to raise hemoglobin by about 1 g/dL, but the actual bump can fall well short of that, and sometimes hemoglobin barely moves at all. The reasons range from straightforward (the patient is still bleeding, or the blood draw was timed poorly) to subtle (the recipient’s immune system is quietly destroying the donated cells, or the spleen is trapping them). Because multiple mechanisms can overlap in the same patient, pinpointing the cause often requires more than just repeating the transfusion.

What a Normal Response Looks Like

Before worrying about a poor result, it helps to know the expected timeline. In a prospective study of stable, non-bleeding hospitalized adults who received a single unit of red blood cells, the average hemoglobin rise was about 0.9 g/dL at 12 hours, 1.4 g/dL at 24 hours, and 1.6 g/dL at 48 hours, with most of the equilibration happening within the first day.¹ The “roughly 1 g/dL per unit” rule of thumb is a reasonable average, but it is just that: an average. Patient-specific factors can easily push the real number higher or lower.

When the Timing of Your Blood Draw Misleads

One of the simplest explanations for a disappointing post-transfusion hemoglobin is that the lab sample was drawn too soon or under less-than-ideal conditions. A narrative review pooling data from studies in the United States, Spain, Colombia, and Thailand found that in hemodynamically stable, non-bleeding adults, hemoglobin values stabilize rapidly, often within 15 to 60 minutes after the transfusion finishes.² That sounds reassuring, but the key qualifier is “stable and non-bleeding.” In patients who are actively receiving large volumes of intravenous fluid, the extra fluid dilutes the blood and masks any hemoglobin rise. If the post-transfusion sample is drawn while fluids are still running wide open, the number on the lab slip may look flat even though the transfusion did its job. Simply waiting until the fluid bolus is finished and rechecking can sometimes resolve the mystery.

Body Size and Its Underappreciated Effect

A packed red-cell unit contains a relatively fixed number of red blood cells. Those cells get distributed through the recipient’s entire blood volume, so the same unit will produce a smaller concentration bump in someone with a larger blood volume. A study of adult transfusion recipients demonstrated a clear, dose-like relationship: patients weighing 40 to 60 kg saw an average hemoglobin rise of about 0.85 g/dL per unit, while those weighing 120 to 140 kg saw only about 0.55 g/dL, a roughly 35 percent difference.³ For every 20-kg increase in weight, the hemoglobin increment dropped by about 6.5 percent. In very large patients, it is not unusual to need an extra unit just to reach the same target a smaller person hits with one.

Ongoing or Occult Bleeding

This is the single most common reason clinicians look for first. If blood is leaving the body at the same rate it is being transfused in, hemoglobin stays flat or continues to fall. The bleeding does not have to be obvious. Slow gastrointestinal oozing from an ulcer or varices, post-surgical drain output that is being underestimated, and retroperitoneal bleeding that is invisible on external exam can all consume transfused red cells without any dramatic sign. When repeated transfusions fail to budge the hemoglobin and no other explanation is found, imaging or endoscopy to look for a hidden bleeding source is often the next step.

Hemolytic Transfusion Reactions

Sometimes the recipient’s immune system attacks and destroys the transfused red cells outright. This can happen quickly or with a frustrating delay.

Acute Hemolysis

Acute hemolytic transfusion reactions typically occur during or within 24 hours of the transfusion. The usual cause is a mismatch between the donor’s and recipient’s red-cell antigens, most commonly an ABO-incompatible unit. The immune response triggers complement activation, which punches holes in the transfused cells (intravascular hemolysis), or it coats the cells with antibodies and complement fragments so that macrophages in the liver and spleen devour them (extravascular hemolysis).⁴ Classic symptoms include fever, chills, flank pain, and dark urine, but in a sedated or critically ill patient these signs can be muted. The lab picture is telling: hemoglobin fails to rise, lactate dehydrogenase climbs, haptoglobin drops, and the urine or plasma may visibly darken.

Delayed Hemolysis

More insidious are delayed hemolytic transfusion reactions, which surface days to weeks after the transfusion. They happen when a patient who was previously sensitized to a minor red-cell antigen has antibody levels too low to detect on the pre-transfusion screen. Exposure to that antigen again through the new unit triggers a rapid antibody surge that destroys both the transfused cells and, in some cases, the patient’s own red cells. In patients with sickle cell disease, delayed reactions involving antibodies to antigens like E, S, Fy(a), or Jk(a) have been documented 7 to 19 days after transfusion.⁵ The hemoglobin may actually end up lower than before the transfusion, a phenomenon sometimes called “hyperhemolysis.” Delayed reactions are notoriously easy to miss because they unfold after the patient has left the transfusion setting, and the falling hemoglobin is sometimes attributed to other causes before anyone considers the possibility.

Autoimmune Hemolytic Anemia

Patients with autoimmune hemolytic anemia produce antibodies against their own red blood cells. When these patients receive a transfusion, the same autoantibodies can attack the donated cells along with the native ones. Cross-matching blood for these patients is notoriously difficult: the antibodies coating the patient’s red cells cause the direct antiglobulin test to be positive, and the autoantibodies in the serum can react with virtually all donor units, making every crossmatch look incompatible. In one series of 36 patients with autoimmune hemolytic anemia, significant alloantibodies (anti-c, anti-Jk(a), and anti-E) were detected on top of the autoantibodies. While 32 patients ultimately received red cells without serious hemolytic reactions, three patients received no transfusion or a delayed transfusion because the positive crossmatches were overinterpreted, and they died as a result.⁶ The takeaway is nuanced: autoimmune hemolysis can genuinely reduce the survival of transfused cells, but excessive caution about transfusing these patients also carries real risk.

The Spleen as a Red-Cell Trap

An enlarged spleen can act like a filter that pulls transfused red cells out of circulation before they have a chance to raise the hemoglobin. The spleen normally recycles old or damaged red cells, but when it is enlarged, it becomes overactive and removes even healthy cells prematurely. In a study comparing cirrhotic patients with and without splenomegaly, those with enlarged spleens experienced only about 80 percent of the hemoglobin rise per transfused unit compared to those with normal-sized spleens, after adjusting for sex and body mass index.⁷ In severe cases, the spleen can sequester transfused cells so aggressively that the pattern on serial hemoglobin checks becomes unmistakable: a brief, small bump followed by a rapid decline.⁸

Patients with thalassemia, myelofibrosis, or advanced liver disease are especially vulnerable. For patients with transfusion-refractory anemia caused by hypersplenism, partial splenic embolization (a procedure that deliberately blocks blood flow to part of the spleen) has been used as a minimally invasive way to reduce the spleen’s trapping ability and allow hemoglobin levels to rise more effectively with transfusion.⁹ Total splenectomy is another option, though it carries a lifelong increase in infection risk.

Sepsis and Chronic Critical Illness

Severe infection and systemic inflammation create a hostile environment for red blood cells, both native and transfused. Inflammatory cytokines suppress the bone marrow’s ability to produce new red cells, and they also shorten the lifespan of circulating ones. In patients with sepsis who developed chronic critical illness, hemoglobin remained significantly depressed at both 3 and 6 months (around 8.9 and 9.2 g/dL, respectively) compared to patients who recovered rapidly (about 10.4 and 11.1 g/dL), despite the chronically ill patients receiving significantly more red-cell transfusions.¹⁰ These patients had persistently elevated markers of inflammation. In this kind of setting, the problem is not a single transfusion failing to work; it is that the underlying inflammatory state chews through red cells faster than they can be replaced. Treating the infection and reducing inflammation is ultimately more important than pouring in additional units.

The Quality of the Blood Unit Itself

Red blood cells change during storage, a phenomenon researchers call the “storage lesion.” As red cells sit in the bag, they lose flexibility, shed membrane fragments, accumulate metabolic waste, and develop surface signals that the recipient’s immune system reads as “remove me.” Studies in healthy volunteers have shown that red cells stored for more than about two weeks undergo measurable extravascular hemolysis after transfusion: the recipient’s spleen and liver macrophages clear a fraction of the transfused cells within hours.¹¹ Indirect bilirubin and iron levels climb with increasing storage time, consistent with breakdown of transfused red cells rather than the patient’s own.

That accelerated clearance means a unit stored near its maximum shelf life may deliver a smaller effective dose of red cells than a freshly collected one. Research has confirmed that storage-related activation of removal signals on the red-cell membrane leads to early immune recognition and destruction after transfusion.¹² Additional concerns include enhanced clearance, nitric oxide scavenging, and immunomodulation, all of which have been linked to less favorable clinical outcomes in some studies.¹³ That said, large randomized trials comparing “fresh” versus “standard-issue” blood have not found dramatic differences in mortality, so the storage lesion is likely a contributor to a suboptimal hemoglobin rise rather than the sole culprit in most cases.

Donor Genetics You Cannot See on the Label

Not all red-cell units are metabolically identical, and some donors carry genetic traits that shorten the lifespan of their red cells in the recipient’s body. A study of sickle cell disease patients receiving biotin-labeled red cells found that the median time to 50 percent survival of transfused cells was about 60 days, but certain donor characteristics pushed that number much lower. Donor G6PD deficiency and alpha-thalassemia trait were both independently associated with decreased red-cell survival in the recipient.¹⁴ In a detailed case study, red cells from a donor with two-gene deletion alpha-thalassemia trait had a half-life of 65 days compared to 86 days for a normocytic unit from a different donor, and the thalassemic cells showed increased surface phosphatidylserine (a signal that flags cells for removal) immediately after transfusion.¹⁵

These findings are part of a growing body of work suggesting that donor metabolic and genetic profiles influence how well a transfusion works. Large-scale analyses have confirmed that previously reported metabolic and genetic predictors of hemoglobin increment remain significant when evaluated together, with individual effect sizes in the range of 0.05 to 0.15 g/dL. Donors carrying certain traits were associated not only with smaller immediate hemoglobin bumps but also with increased likelihood of the recipient needing additional transfusions down the line.¹⁶ Most blood banks do not currently screen for traits like G6PD deficiency in donors, so this is an invisible variable that can contribute to a puzzlingly poor transfusion response.

Alloimmunization and the Importance of Antigen Matching

Patients who receive repeated transfusions are at risk of developing antibodies against minor red-cell antigens they lack but the donors carry. Once alloimmunized, future transfused cells carrying the offending antigen will be targeted for destruction. This is a major concern for patients with sickle cell disease, thalassemia, and myelodysplastic syndromes who depend on regular transfusions. A retrospective cohort study found that patients receiving standard ABO and RhD matching had an alloimmunization rate of about 24.6 percent, while those receiving extended antigen matching (covering Rh variants and Kell in addition to ABO and RhD) had a rate of just 7.1 percent.¹⁷ Extended matching is not yet universal practice, but for chronically transfused patients it can meaningfully reduce the chance of developing the very antibodies that cause hemolytic reactions and blunt the hemoglobin response.

Microangiopathic and Mechanical Destruction

In conditions like thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome, disseminated intravascular coagulation, and some mechanical heart valve situations, red blood cells are physically shredded as they pass through damaged or obstructed small blood vessels. This process does not discriminate between the patient’s own cells and freshly transfused ones. Transfusing red cells into a patient with active microangiopathic hemolysis is a bit like pouring water into a bucket with a hole in it: the cells are destroyed almost as fast as they are given, and hemoglobin fails to rise until the underlying process is controlled. The classic lab clue is the presence of fragmented red cells (schistocytes) on the peripheral blood smear, along with elevated LDH, low haptoglobin, and a rising bilirubin.

Transfusion Process Errors

Sometimes the issue is not biology at all but logistics. National hemovigilance data from the United States reported over 63,900 transfusion-related errors across 80 acute care facilities between 2014 and 2022. The most common errors occurred during patient blood sample collection (about 34 percent) and sample handling (about 26 percent). Of the incidents with completed forms, the vast majority were near misses, but over a third of those near misses resulted in a discarded blood product.¹⁸ Errors like mislabeled samples, units given to the wrong patient, or units that were improperly stored before administration can all contribute to a transfusion that appears to “not work.” If the pre-transfusion sample was drawn from the wrong patient or the wrong line, the baseline hemoglobin itself may be inaccurate, making the post-transfusion number look flat even when the cells were delivered correctly.

What Can Be Done When Hemoglobin Will Not Budge

The approach depends entirely on identifying which of the above mechanisms is at play, and more than one can operate simultaneously. The initial workup usually includes checking for signs of hemolysis (LDH, haptoglobin, indirect bilirubin, a direct antiglobulin test), reviewing fluid balance to rule out dilution, examining the patient for sources of bleeding, and confirming that the post-transfusion lab was drawn at an appropriate time and from a reliable site.

For patients with hypersplenism-related refractoriness, the standard options range from conservative management with regular transfusions and iron chelation, to partial splenic embolization for acute situations, to total splenectomy for severe cases. Hematopoietic stem cell transplantation remains the only potentially curative intervention for conditions like thalassemia major.⁹ For patients with refractory anemia driven by inadequate red-cell production, erythropoietin-stimulating agents can help, though some patients develop functional iron deficiency during treatment and require supplemental iron before they respond.¹⁹

For alloimmunized patients, the solution is better antigen matching. Extended phenotype or genotype matching for Rh and Kell antigens has been shown to significantly reduce the rate of new antibody formation and improve transfusion effectiveness in chronically transfused populations.¹⁷ And for cases where the transfused cells are being destroyed by an underlying microangiopathic process, the priority is treating the root cause, whether that means plasma exchange for TTP, treating the infection driving DIC, or managing the underlying condition. Pouring in more units without addressing the destruction is expensive, risky, and futile.

When Donor Screening Might Change the Equation

The recognition that donor genetics affect transfusion outcomes is relatively new and has not yet translated into routine blood-bank practice. Most donor centers screen for infectious disease markers and ABO/Rh type but do not test for traits like G6PD deficiency, alpha-thalassemia, or metabolic phenotypes that influence red-cell storage quality and post-transfusion survival. Research has shown that these donor traits carry effect sizes that, while individually modest, can stack. A unit from a G6PD-deficient donor stored for five weeks and transfused into a patient with an enlarged spleen could plausibly deliver far less effective hemoglobin increment than a fresh unit from a metabolically favorable donor given to a small patient with a normal spleen.¹⁶ Whether blood banks will eventually incorporate donor genetic screening into routine operations is an open question, but the evidence base is growing. For now, clinicians managing patients with consistently disappointing transfusion responses should consider the possibility that the units themselves, not just the recipient, may be part of the problem.